Bluejay Diagnostics (BJDX) Debt Ratio (2020 - 2021)

Bluejay Diagnostics (BJDX) reported Debt Ratio of 0.0 for Q4 2021, down 99.31% on a YoY basis from 0.08 in Q4 2020, and down 98.35% sequentially from 0.03 in Q3 2021.

Bluejay Diagnostics (BJDX) Debt Ratio (2020 - 2021) Analysis & Trends

Bluejay Diagnostics (BJDX) has 2 years of Debt Ratio data on file, last reported at 0.0 in Q4 2021.

  • For the quarter ending Q4 2021, Debt Ratio fell 99.31% year-over-year to 0.0; the trailing twelve-month figure through Dec 2021 stood at 0.0 (down 99.31% YoY), and the FY2021 full-year result was 0.0, down 99.31% from the prior year.
  • Debt Ratio declined to 0.0 in Q4 2021, from 0.03 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.08 in Q4 2020 to a low of 0.0 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 0.31
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 0.32
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 0.30
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 0.25
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn 0.04
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn -
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 0.30
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 0.27
9 Smith & Nephew 25.80 Bn 25.22 Bn - 0.30
10 Bluejay Diagnostics 2,754.24 2,754.24 - -

Historic Data

Download Data
DateValue
Dec 31, 2021 0.00
Sep 30, 2021 0.03
Dec 31, 2020 0.08